Literature DB >> 7083559

Verapamil and calcium-stimulated enzyme efflux from skeletal muscle.

R Anand, A E Emery.   

Abstract

An early and significant biochemical abnormality in Duchenne's muscular dystrophy is an increase in intracellular calcium. We have found that the "calcium-blocker" drug verapamil inhibits calcium-stimulated efflux of creatine kinase (EC 2.7.3.2) and lactate dehydrogenase (EC 1.1.1.27) in vitro from normal human skeletal muscle at therapeutic concentrations. Such a calcium blocker might therefore be useful in the treatment of Duchenne's muscular dystrophy.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7083559

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


  3 in total

1.  Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Nalinda B Wasala; Yongping Yue; William Lostal; Lakmini P Wasala; Nandita Niranjan; Roger J Hajjar; Gopal J Babu; Dongsheng Duan
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

2.  A double-blind placebo controlled trial of diltiazem in Duchenne dystrophy.

Authors:  W Pernice; R Beckmann; U P Ketelsen; M Frey; B Schmidt-Redemann; K P Haap; R Roehren; M Sauer
Journal:  Klin Wochenschr       Date:  1988-07-01

3.  Ca2+-ATPase deficiency in a patient with an exertional muscle pain syndrome.

Authors:  D J Taylor; M J Brosnan; D L Arnold; P J Bore; P Styles; J Walton; G K Radda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.